Table 1.
Virus Assessed | In Vitro Virucidal Suspension Test, Results | Model Specifics + Trypsin Inhibitor (TI) Used |
---|---|---|
SARS-CoV-2 and HCoV-229E [13] |
CZ-MD inactivated SARS-CoV-2 and HCoV-229E in vitro by 98.3% and 99.9%, respectively. | Direct mixing of CZ-MD formulation with virus. Reaction mixture was mixed with equal volume of “neutralizer” before dilution and culture with host cells in MEM in presence of TI: TI used: for SARS-CoV-2: 10% NCS, for HCoV-229E: 10% FBS |
Common cold (CC) virus [37,38] |
CZ-MD inactivated rhinovirus 1A: 91.7% (1.08 log10); rhinovirus 42: 92.8% (1.14 log10); hIV virus H3N2: 96.9% (1.51 log10); RSV: 99.9% (2.94 log10); adenovirus T2: 64.5% (0.45 log10); human coronavirus [38]. | Direct mixing of CZ-MD formulation with virus. Trypsin was neutralized prior to dilution and exposure to host cells. TI used: FBS |
Rhinovirus 1A [39] |
Trypsin delayed Rhinovirus-1A infection of RD cells in vitro by 2 days. | Direct mixing of cod trypsin with virus. Trypsin was neutralized prior to dilution and exposure to host cells TI used: benzamidine |
CZ-MD = Coldzyme medical device; Foetal Bovine Serum = FBS; Newborn Calf Serum = NCS; human Influenza A = hIV; Respiratory Syncytial virus (RSV); RD-cells: presumably a human rabdosarcoma cell line (abbreviation not specified in abstract; MEM = minimal essential media; TI = trypsin inhibitor [39]).